July 30, 2016
Recommended Topic Related To:


"The U.S. Food and Drug Administration today granted accelerated approval to Praxbind (idarucizumab) for use in patients who are taking the anticoagulant Pradaxa (dabigatran) during emergency situations when there is a need to reverse Pradaxa&rsqu"...



Zn-DTPA Side Effects Center

Medical Editor: John P. Cunha, DO, FACOEP

Last reviewed on RxList 6/8/2016

Zn-DTPA (pentetate zinc trisodium) Injection is a chelating agent used to treat patients with known or suspected internal contamination with plutonium, americium, or curium to increase the rates of elimination. Common side effects of Zn-DTPA include:

The dose of Zn-DTPA for adults and adolescent is a single 1.0 gram initial dose administered intravenously. The pediatric dose (less than 12 years of age) is a single initial dose of 14 mg/kg administered intravenously not to exceed 1.0 gram. Zn-DTPA may interact with other drugs. Tell your doctor all medications and supplements you use. During pregnancy, Zn-DTPA should be used only if prescribed. Radiocontaminants are known to pass into breast milk. Women with known or suspected internal contamination with radiocontaminants should not breastfeed, whether or not they are receiving chelation therapy. Precautions should be taken when discarding breast milk.

Our Zn-DTPA (pentetate zinc trisodium) Injection Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What is Prescribing information?

The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.

Zn-DTPA FDA Prescribing Information: Side Effects
(Adverse Reactions)


In the U.S. Registry, a total of 646 individuals received at least one dose of either Ca-DTPA or Zn-DTPA (pentetate zinc trisodium injection) . Of these, 62 received Zn-DTPA (pentetate zinc trisodium injection) by one or more routes of administration. Forty-eight individuals were dosed by intravenous administration, 18 by inhalation and 8 by other or unknown routes of administration.

Of the individuals that received Zn-DTPA (pentetate zinc trisodium injection) , 23/62 (37%) received one dose and 8 (13%) received two doses. The remaining 31 individuals received three or more doses. The largest number of Zn-DTPA (pentetate zinc trisodium injection) doses to a single individual was 574 doses delivered over 3.5 years.

Overall, the presence or absence of adverse events was recorded in 310/646 individuals. Of these 19 (6.1%) individuals reported at least one adverse event. The total number of recorded adverse events was 20. Of the 20 adverse events, 1 individual treated with Zn-DTPA (pentetate zinc trisodium injection) reported headache, lightheadedness, and pelvic pain.

Two individuals experienced cough and/or wheezing with nebulized Ca-DTPA therapy however there was no report of such events with nebulized Zn-DTPA (pentetate zinc trisodium injection) .

Read the entire FDA prescribing information for Zn-DTPA (Pentetate Zinc Trisodium Injection)

Report Problems to the Food and Drug Administration


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Women's Health

Find out what women really need.